Is LPTH a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Germanium substitution is a materials moat, not just a product line, with revenue (ttm) at ~$63M, up ~87% year over year. The bear case rests on valuation is the first-order risk: at roughly $950M to $1.0B of market value against ~$63M of trailing twelve-month revenue, the stock trades near 15x to 16x sales while still reporting a trailing net loss of about $23M, so the price already discounts several years of backlog conversion going right. Analysts covering it are spread from $15.00 to $17.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Valuation is the first-order risk: at roughly $950M to $1.0B of market value against ~$63M of trailing twelve-month revenue, the stock trades near 15x to 16x sales while still reporting a trailing net loss of about $23M, so the price already discounts several years of backlog conversion going right. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $15.00, -1.1% from the $15.17 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Germanium substitution is a materials moat, not just a product line. China's germanium export licensing has made the standard infrared lens material scarce and expensive for US and allied defence buyers, with ingot prices setting records after the restrictions took effect. The most optimistic analyst target on LPTH is $17.00, +12.1% from the $15.17 price. That figure is only reachable if this thesis works close to its best case.

Valuation is the first-order risk: at roughly $950M to $1.0B of market value against ~$63M of trailing twelve-month revenue, the stock trades near 15x to 16x sales while still reporting a trailing net loss of about $23M, so the price already discounts several years of backlog conversion going right. Dilution history is the second: common shares outstanding went from ~42.9M at June 30, 2025 to ~61.2M at March 31, 2026, and pro forma for the June 2026 placement and Series G preferred conversions the count is closer to ~70M, meaning existing holders funded the growth by giving up roughly a third of the company inside a year. Execution risk is real and concentrated, because three acquisitions in three years must be integrated while a cooled camera family is redesigned onto new glass, and a slipped qualification pushes revenue by quarters rather than weeks. Customer and programme concentration cuts both ways, since single orders of $13M to $18M are large relative to the revenue base and their delivery schedules extend into 2027. Worth noting factually: Purcell and Lefkowitz issued a shareholder alert in September 2023 saying it was investigating potential breaches of fiduciary duty by the board, which is a law-firm press release rather than a filed complaint, and no securities-fraud class action against the company appears on a docket. Manufacturing exposure in China and Latvia adds tariff, export-control and geopolitical friction to a business whose main selling point is supply chain independence from China. The most pessimistic published target is $15.00, -1.1% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

LightPath Technologies designs and manufactures precision optics with a specialty in the infrared, increasingly for defence and thermal imaging systems.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Germanium substitution is a materials moat, not just a product line) stalling in the reported numbers rather than in the narrative, the risk above (valuation is the first-order risk: at roughly $950M to $1.0B of market value against ~$63M of trailing twelve-month revenue, the stock trades near 15x to 16x sales while still reporting a trailing net loss of about $23M, so the price already discounts several years of backlog conversion going right) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Infrared and visible optics, and increasingly the finished systems built from them. The catalogue runs from molded aspheric lenses and BlackDiamond chalcogenide infrared optics through multi-element assemblies to cooled and uncooled thermal camera systems sold under the G5 Infrared and Visimid brands, mostly into defence, border security and industrial imaging.

Three things stacked. Revenue more than doubled year over year on the G5 and Visimid acquisitions, backlog rose ~196% in nine months to ~$110.6M on named defence awards, and China's germanium export restrictions gave LightPath's germanium-free BlackDiamond glass a supply-chain reason to win Western defence designs. The 52-week range of ~$3.36 to ~$18.94 shows how much of that repriced in one year.

Not on a GAAP basis. Fiscal third-quarter 2026 showed a net loss of ~$4.1M, or ~$0.07 per share, and the trailing twelve-month net loss is around $23M. Adjusted EBITDA has been positive for three consecutive quarters (~$1.1M in the latest one), so the operating trend improved well before the bottom line did.